申请人:Novo Nordisk A/S
公开号:US05512562A1
公开(公告)日:1996-04-30
Tricyclic benzazepines having the general formula ##STR1## wherein A together with the .alpha.- and .beta.-marked carbon atoms is a cyclopentene, cyclohexene, furan, dihydrofuran, pyran, dihydropyran, thiophene, oxazole, pyrrole, pyrroline, tetrahydropyridine or dioxole ring, R.sup.1 is H or alkyl, R.sup.2 and R.sup.3 independently are H, alkoxy, halogen, nitro, cyano or hydroxy, or R.sup.2 and R.sup.3 together may form a furan, dihydrofuran, cyclopentene or dioxole ring and R.sup.4 is H, alkoxy, nitro, cyano, hydroxy or halogen, or a pharmaceutically acceptable salt thereof, are useful in treatment of certain disorders in the central nervous system, e.g., psychosis, pain, depression, sleep disturbances, dyskinesia, Parkinson's disease, stroke.
三环苯并蒽啉具有通用式##STR1##其中A与α-和β-标记的碳原子一起是环戊烯,环己烯,呋喃,二氢呋喃,吡喃,二氢吡喃,噻吩,噁唑,吡咯,吡咯烷,四氢吡啶或二噁烷环,R.sup.1为H或烷基,R.sup.2和R.sup.3独立地是H,烷氧基,卤素,硝基,氰基或羟基,或R.sup.2和R.sup.3一起可以形成一个呋喃,二氢呋喃,环戊烯或二噁烷环,R.sup.4为H,烷氧基,硝基,氰基,羟基或卤素,或其药用盐,可用于治疗中枢神经系统中的某些疾病,例如精神病,疼痛,抑郁症,睡眠障碍,运动障碍,帕金森病,中风。